Long-Term Efficacy and Safety of Dupilumab in Patients with Atopic Dermatitis: A Single-Centre Retrospective Study

Introduction: There are few long-term effectiveness and safety data for dupilumab in the treatment of atopic dermatitis (AD). The aim of this study was to evaluate efficacy and safety of dupilumab for up to three years after treatment initiation. Materials and Methods: We collected data from patients ≥ 12 years with severe AD who started dupilumab at the Dermatology Clinic of the Turin University Hospital between December 2018 and October 2022. Clinic and patient reported outcomes were evaluated from baseline, up to 3 years (T9), every 4 months. Results: A total of 418 patients were observed. A progressive decrease in the meanEASI was observed: from 23.64 at baseline to 2.31 at T9. Similar trends were observed in patients’ reported outcomes. The achievement of EASI75 and EASI90 was observed in 75.58% of patients and 53.49%, respectively, at T1 (4 months), and in 92.55% and 80.85% at T9; DLQI 0/1 was achieved at T9 in 61.7%. Mean NRSpp ≤ 4 was achieved at T9 in 91.5% (86 out of 94 patients). The most common adverse event was conjunctivitis occurring in 13% of patients on average at each timepoint analyzed. Conclusions: Dupilumab proved to be effective and safe for the treatment of AD in clinical practice, up to 3 years.